Brief: Zydus Lifesciences Says FDA Accepts Sentynl's Cutx-101 NDA Resubmission
Dec 15 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS: FDA ACCEPTS SENTYNL'S CUTX-101 NDA RESUBMISSION NEW PDUFA DATE FOR CUTX-101 SET FOR JANUARY 14, 2026 Source text: ID:nBSE58TbJm Further company coverage: ZYDU.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zydus Lifesciences
See all newsIndia's Zydus Lifesciences posts lower profit as expenses outpace revenue growth
Brief: Zydus Lifesciences Q2 Consol Net Profit 9.26 Billion Rupees
Brief: Zydus Lifesciences Says Zylidac Bio And Prolific Machines Partner
Brief: Zydus Lifesciences Receives U.S. FDA Approval For Estradiol And Levonorgestrel Transdermal System
Brief: Zydus Lifesciences Says Zydus Sunshine Lifesciences Signs Agreement To Establish A Pharmaceutical Manufacturing Facility In Sri Lanka